MAPT and dementia: We use data from Alzheimer’s Disease and Neuroimaging Initiative (ADNI) to assess whether the addition of MRI volumetric measures in key regions of the brain and CSF-based biomarkers (Aß and P-tau) improve cognitive status classification, that is classification as having dementia, cognitive impairment without dementia or being cognitively normal, relative to cognitive performance examinations normally included in population surveys.